Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

63.82 +1.44 (+2.31%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 30, 2023

Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results.

Via Benzinga

Recap: Arrowhead Pharma Q4 Earnings ↗

November 29, 2023

Via Benzinga

Earnings Scheduled For November 29, 2023 ↗

November 29, 2023

Companies Reporting Before The Bell • CollPlant Biotechnologies (NASDAQ:CLGN) is likely to report quarterly loss at $0.13 per share on revenue of $3.50 million.

Via Benzinga

Earnings Outlook For Arrowhead Pharma ↗

November 28, 2023

Via Benzinga

Analyst Expectations for Arrowhead Pharma's Future ↗

September 19, 2023

Via Benzinga

Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK ↗

October 31, 2023

GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023 ↗

September 19, 2023

Via Benzinga

Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public' ↗

September 08, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,

Via Benzinga

Analyst Ratings for Arrowhead Pharma ↗

August 08, 2023

Via Benzinga

Analyst Expectations for Arrowhead Pharma's Future ↗

July 21, 2023

Via Benzinga

Expert Ratings for Arrowhead Pharma ↗

June 30, 2023

Via Benzinga

Where Arrowhead Pharma Stands With Analysts ↗

May 24, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗

July 21, 2023

Via Benzinga

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million ↗

June 15, 2023

Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.

Via Investor's Business Daily

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

The Latest Analyst Ratings for Arrowhead Pharma ↗

May 03, 2023

Via Benzinga

Is Arrowhead Pharmaceuticals a Buy Now? ↗

April 16, 2023

The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.

Via The Motley Fool

Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung Disease ↗

June 01, 2023

Arrowhead CEO Christopher Anzalone discusses expectations for ARO-RAGE in lung disease.

Via Investor's Business Daily

What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder ↗

May 23, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023 ↗

May 12, 2023

Via Benzinga

Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday ↗

April 25, 2023

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

Via The Motley Fool

Expert Ratings for Arrowhead Pharma ↗

April 12, 2023

Via Benzinga

Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 25, 2023

Gainers

Via Benzinga

Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars ↗

April 25, 2023

Via Benzinga

Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday ↗

April 25, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 25, 2023

Via Benzinga

Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗

April 12, 2023

SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...

Via Benzinga

Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 12, 2023

Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023 ↗

April 12, 2023

Via Benzinga

2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street ↗

April 04, 2023

Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

Headline News about Arrowhead Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today